vascuCAP vs EchoNext

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

vascuCAP

by Elucid Bioimaging

EchoNext

by Pathway Labs

AI Verdict

Both vascuCAP and EchoNext are FDA-cleared AI tools in cardiology that offer clinical decision support. However, vascuCAP focuses on advanced CT angiography analysis for plaque characterization and cardiovascular risk assessment, while EchoNext analyzes standard ECGs to detect hidden structural heart disease. Therefore, vascuCAP is more suitable for detailed arterial plaque analysis, whereas EchoNext is designed for broader, earlier-stage screening of structural heart conditions.

Choose vascuCAP if…

Choose vascuCAP if you need detailed, histologically-validated quantification and characterization of atherosclerotic plaque from CT angiography to assess cardiovascular risk and guide personalized treatment decisions for stroke and heart attack prevention. This tool is ideal for specialists in cardiology, radiology, and vascular surgery who require precise 3D visualization of arterial vessels and plaque composition.

View vascuCAP →

Choose EchoNext if…

Choose EchoNext if you need a non-invasive, AI-powered screening tool to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension, from standard ECGs. This tool is best suited for broad clinical access, from major hospitals to community practices, to identify at-risk patients who may require further diagnostic testing like echocardiograms.

View EchoNext →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	vascuCAP	EchoNext
Pricing	Contact for pricing	Starts at $600/month
Deployment	Cloud and on-premise	Available through the OpenEvidence clinical decision support platform.
BAA Available	Unknown	Yes AI-estimated
FDA Status	1 AI-estimated	Yes AI-estimated
HIPAA	Unknown	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

EchoNext

EchoNext is deployed through the OpenEvidence clinical decision support platform, which is used by over half of US clinicians, suggesting a streamlined integration into existing workflows and a potentially familiar user experience. In contrast, while vascuCAP (now ElucidVivo/PlaqueIQ) integrates with DICOM and PACS/EMR, there is less specific information about its user interface or ease of adoption in the provided data.

Clinical Value

vascuCAP

vascuCAP (now ElucidVivo/PlaqueIQ) offers histologically-validated plaque quantification and characterization, providing objective and detailed insights into plaque composition, which is considered the gold standard. This level of detail supports personalized treatment decisions and risk stratification for stroke and heart attack. EchoNext, while valuable for detecting hidden structural heart disease from ECGs, provides a screening function rather than the in-depth diagnostic analysis offered by vascuCAP.

Pricing & Value

EchoNext

EchoNext offers transparent tiered pricing starting at $600/month, including details on implementation fees and annual discounts, allowing potential users to better understand the cost. In contrast, vascuCAP's pricing is listed as 'contact for pricing,' which lacks transparency. While Elucid's Plaque-IQ has established CPT codes and reimbursement, the initial cost structure for the software itself is not publicly available.

Enterprise Readiness

EchoNext

EchoNext is designed for broad access, from major hospitals to community practices, and its deployment through the OpenEvidence platform, used by over half of US clinicians, indicates a strong strategy for widespread adoption and integration. vascuCAP also offers cloud and on-premise deployment and DICOM integration, but its enterprise reach is not as explicitly detailed in the provided information.

Innovation

vascuCAP

vascuCAP (now ElucidVivo/PlaqueIQ) stands out for its unique histologically-validated plaque quantification, which allows for objective characterization of plaque composition, including lipid-rich necrotic core and intraplaque hemorrhage. This provides a deeper, more precise understanding of cardiovascular risk than traditional methods. EchoNext is innovative in its ability to detect hidden structural heart disease from standard ECGs, but the histological validation of plaque composition by Elucid's tool represents a more fundamental advancement in diagnostic imaging.

Support & Docs

Tie

Both tools are FDA-cleared and operate in the medical domain, implying a need for robust support and documentation. However, the provided information for both vascuCAP (now ElucidVivo/PlaqueIQ) and EchoNext does not offer specific details regarding their customer support channels, documentation availability, or training programs. Therefore, it is not possible to definitively pick a winner in this dimension.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	vascuCAP	EchoNext
Tool Name	vascuCAP (now ElucidVivo/PlaqueIQ)	EchoNext
Company	Elucid Bioimaging	Pathway Labs
Description	FDA-cleared AI software for non-invasive CT angiography analysis, quantifying plaque composition and assessing cardiovascular risk to optimize treatment decisions.	FDA-cleared AI tool that analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension.
Categories	Cardiology AI, Clinical Decision Support & Reference	Cardiology AI, Clinical Decision Support & Reference, Lab & Diagnostics
Key Features	AI-enabled CT angiogram analysis, Histologically-validated plaque quantification and characterization, 3D visualization of arterial vessels and plaque, Risk stratification for stroke and heart attack, Support for personalized treatment decisions, Quantification of lipid-rich necrotic core, calcification, non-calcified matrix, intraplaque hemorrhage, DICOM integration and PACS/EMR interoperability, Cloud and on-premise secure deployment options	AI-powered ECG analysis, Detection of hidden structural heart disease, Identifies heart failure risk, Screens for valve disease, Detects pulmonary hypertension indicators, Utilizes standard 12-lead ECGs, FDA-cleared technology, Non-invasive diagnostic support

Videos

Demos, reviews, and walkthroughs featuring vascuCAP and EchoNext.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate into existing clinical workflows and EHR systems?

vascuCAP integrates with DICOM and offers PACS/EMR interoperability, and its analysis is performed on-site in minutes, providing information to aid treatment decisions. EchoNext is available through the OpenEvidence clinical decision support platform, which is used by many U.S. clinicians, allowing its screening output to be directly accessible within existing workflows without requiring a separate system.

What is the accuracy and sensitivity of each tool in detecting cardiac conditions?

vascuCAP's algorithms for plaque quantification and characterization are histologically validated, and studies have shown it to be more accurate in predicting stroke than stenosis-based methods. EchoNext accurately identified 77% of structural heart problems from ECGs alone in a 2025 study, outperforming cardiologists who were 64% accurate with the same ECGs. EchoNext has shown consistent performance across diverse patient demographics and clinical contexts.

For which specific cardiac specialties are these tools best suited?

vascuCAP is designed for cardiology, radiology, and vascular surgery, focusing on non-invasive CT angiography analysis to quantify plaque composition and assess cardiovascular risk. EchoNext is suitable for cardiology, family medicine, hospital medicine, and internal medicine, as it analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension.

What is the typical learning curve for physicians to effectively use each tool?

While specific learning curve details aren't provided, vascuCAP's on-site analysis in minutes suggests a streamlined process for obtaining results. EchoNext's integration with the OpenEvidence platform aims to embed its output into common clinical workflows, potentially reducing the learning curve by leveraging a familiar interface.

What kind of audit-trail features do these tools offer to support clinical documentation and review?

The provided information does not explicitly detail the audit-trail features for either vascuCAP or EchoNext. However, in general, AI tools in healthcare need to address challenges like data interoperability and prospective evaluation for successful implementation.

How quickly can a practice expect to see value after implementing each tool (time-to-value)?

The time-to-value for vascuCAP is suggested to be relatively quick, as its analysis is performed on-site in minutes, providing immediate insights for treatment decisions. For EchoNext, its availability through the OpenEvidence platform aims to accelerate its integration into existing clinical workflows, suggesting a faster path to realizing its benefits in identifying structural heart disease.

Are there clinical case studies or customer references available to demonstrate the real-world impact of these tools?

For vascuCAP, interim results from the CRISP study demonstrated its AI technology significantly outperformed stenosis-based guidelines in predicting major adverse neurological events. For EchoNext, a 2025 study published in Nature highlighted its ability to identify structural heart problems more accurately than cardiologists, and a peer-reviewed case in Nature Medicine described EchoNext flagging severe, undiagnosed heart failure in a patient who received a heart transplant.